Fundz

Natera

Austin, Texas, United States · Biotechnology, Genetics, Health Care · 4,500 employees

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the

Recent signals

  • Jun 04, 2026: Natera and CytoDyn Enter Strategic Partnership to Enhance ctDNA Insights for Metastatic Colorectal Cancer Development.
  • Dec 05, 2025: Acquired Natera acquires Foresight Diagnostics for $275 million
  • Dec 04, 2025: SEC 8-K (2.01): On December 4, 2025, Natera, Inc. completed the acquisition of Foresight Diagnostics Inc., a cancer diagnostics company, under an Agreement and Plan of Merger dated October 10, 2025. As part of the transaction, Natera will issue a total of approximately 1,952,565 shares of its common stock to the stockholders of Foresight, which includes 1,127,982 shares as initial consideration and an estimated 824,583 additional shares that may become issuable. This acquisition strategically enhances Natera's capabilities in molecular residual disease detection for B-cell lymphomas, positioning the company to expand its market presence in innovative cancer diagnostics. The acquisition is expected to significantly impact Natera's business operations and growth trajectory.
  • Nov 21, 2024: Launched Natera, Inc. Achieves Milestone with Over 100 Publications on Signatera, a Tumor-informed MRD Test.
  • Jan 22, 2024: Acquired Natera Acquires Reproductive Health Assets from Invitae
  • Sep 18, 2023: Natera Announces Senior Leadership Appointments

See plans & pricing → Track Natera’s funding, hiring, and signals — with verified contacts — on Fundz.